Skip to main content
ARGX
NASDAQ Life Sciences

argenx Launches $2.2B Tender Offer for Forte Biosciences at $77/Share

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$868.54
Mkt Cap
$54.104B
52W Low
$631.47
52W High
$953.58
52W Position info
38% above low
Off High info
8.9% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

ARGX sits 38% above its 52-week low of $631.47.

Summary

argenx SE formally launched its $2.2 billion all-cash tender offer for Forte Biosciences at $77.00 per share. The offer expires August 26, 2026, and the Forte board unanimously recommends stockholders tender their shares.


Key Events · M&A and Partnerships · ARGX

  • Tender Offer Commenced

    Through its subsidiary Avena Merger Sub Inc., argenx SE formally launched a tender offer to acquire all outstanding shares of Forte Biosciences for $77.00 per share in cash, valuing the deal at approximately $2.2 billion. The offer expires on August 26, 2026.

  • Forte Board Unanimously Recommends Tender

    The Forte board unanimously determined the offer is fair and in the best interest of stockholders, recommending they tender their shares. Directors and executive officers, holding ~1% of shares, have agreed to tender.

  • No Financing Condition; Cash on Hand

    The offer is not subject to any financing condition. argenx expects to fund the $2.2 billion purchase price entirely with cash on hand, reflecting its strong balance sheet.

  • HSR Waiting Period Expires August 18

    The required HSR Act filings were made on August 3, 2026, and the waiting period is set to expire on August 18, 2026, unless extended or terminated early.


Analysis · ARGX · Life Sciences

argenx SE has formally launched its all-cash tender offer to acquire Forte Biosciences for $77.00 per share, a deal valued at approximately $2.2 billion. The offer is now open and will expire on August 26, 2026, unless extended. This follows the July 27 announcement and represents the definitive step to acquire Forte's anti-CD122 antibody FB102, which has shown promise in autoimmune indications. The Forte board unanimously recommends stockholders tender their shares. The transaction is not subject to a financing condition, and argenx expects to fund it with cash on hand. The HSR waiting period is set to expire on August 18, 2026. If the minimum tender condition is met, argenx will complete a second-step merger without a stockholder vote, taking Forte private. The deal includes a $65 million termination fee payable by Forte under certain circumstances.

How filings like this one have moved

In the 30 days to Nov 10, 2026, 52.5% of the 204 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.68%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ARGX was trading at $868.54 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $54.1B. The 52-week trading range was $631.47 to $953.58. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ARGX - Latest Insights

ARGX
Nov 09, 2026, 8:01 AM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $945.64
Real-time Price: $963.43 info
Change: +$17.78 (+2%) info
Market Cap: $60.254B info
ARGX
Nov 09, 2026, 6:01 AM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $894.64
Real-time Price: $963.43 info
Change: +$68.78 (+8%) info
Market Cap: $60.254B info
ARGX
Oct 22, 2026, 8:20 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $854.00
Real-time Price: $963.43 info
Change: +$109.42 (+13%) info
Market Cap: $60.254B info
ARGX
Oct 08, 2026, 6:51 AM EDT
Source: Seeking Alpha
Importance Score:
8
Price at Filing: $795.20
Real-time Price: $963.43 info
Change: +$168.22 (+21%) info
Market Cap: $60.254B info
ARGX
Oct 08, 2026, 6:01 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $791.00
Real-time Price: $963.43 info
Change: +$172.42 (+22%) info
Market Cap: $60.254B info